# REMINET (NCT02288377)

> A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

No report yet. It can be ordered.

- Drugs tested: lanreotide
- Indication: non-resectable duodeno-pancreatic neuroendocrine tumors after first-line treatment

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02288377
- Phase: PHASE2, PHASE3
- Status: TERMINATED
- Sponsor: Federation Francophone de Cancerologie Digestive
- Conditions: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
- Interventions: lanreotide; Placebo
- Enrollment: 53
- Primary outcome: Proportion of Patients Alive and Progression-free at 6 Months

## Indexed commentary on REMINET so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=reminet-nct02288377